Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618826 · ClinicalTrials.gov registry record · Phase 2
A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00618826: Completed Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00618826 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00618826, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to look at a new chemotherapy schedule in metastatic breast cancer.
Primary Outcome
Time from study entry to disease progression or death
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT00618826 record still lists
NCT00618826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which Paclitaxel is the first listed.
NCT00618826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00618826 about?
NCT00618826 is a clinical study titled "A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer". The purpose of this study is to look at a new chemotherapy schedule in metastatic breast cancer.
What is the current status of trial NCT00618826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2006-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00618826?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), Avastin (DRUG).
Who is sponsoring clinical trial NCT00618826?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00618826's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia